The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing
Open accessAbstract
Psychedelic microdosing describes the ingestion of near-threshold perceptible doses of classic psychedelic substances. Anecdotal reports and observational studies suggest that microdosing may promote positive mood and well-being, but recent placebo-controlled studies failed to find compelling evidence for this. The present study collected web-based mental health and related data using a prospective (before, during and after) design. Individuals planning a weekly microdosing regimen completed surveys at strategic timepoints, spanning a core four-week test period. Eighty-one participants completed the primary study endpoint. Results revealed increased self-reported psychological well-being, emotional stability and reductions in state anxiety and depressive symptoms at the four-week primary endpoint, plus increases in psychological resilience, social connectedness, agreeableness, nature relatedness and aspects of psychological flexibility. However, positive expectancy scores at baseline predicted subsequent improvements in well-being, suggestive of a significant placebo response. This study highlights a role for positive expectancy in predicting positive outcomes following psychedelic microdosing and cautions against zealous inferences on its putative therapeutic value.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Agreeableness and openness to experience did not change at all after MD compared to baseline in the current study, contrasting results from earlier MD studies (12, 28).”
From Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Agreeableness was increased after MD in a general population sample (12)”
From Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study (2023) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“but other studies did not find this effect in a general population sample (12) and a general sample without individuals diagnosed with a mood, anxiety, substance use, psychotic or dissociative disorder (13).”
From Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study (2023) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Neuroticism decreased after MD in healthy adults (29) and a general population sample (12)”
From Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study (2023) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“The decrease in neuroticism reported here is consistent with two previous prospective MD studies (12, 29).”
From Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study (2023) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Kaertner et al. (2021) found that positive expectancy scores regarding the effects of microdosing at baseline predicted subsequent improvements in wellbeing.”
From Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study (2023) · cites this paper as Kaertner et al. (2021)
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A very brief measure of the Big-Five personality domains
Gosling, S. D., Rentfrow, P. J., & Swann, W. B. (2003) · Journal of Research in Personality · doi:10.1016/s0092-6566(03)00046-1 · Cited by 8,307
The brief resilience scale: Assessing the ability to bounce back
Smith, B. W., Dalen, J., Wiggins, K., Tooley, E., Christopher, P., & Bernard, J. (2008) · International Journal of Behavioral Medicine · doi:10.1080/10705500802222972 · Cited by 6,439
The Warwick-Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation
Tennant, R., Hiller, L., Fishwick, R., Platt, S., Joseph, S., Weich, S., Parkinson, J., Secker, J., & Stewart-Brown, S. (2007) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-5-63 · Cited by 5,031
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Marteau, T. M., & Bekker, H. (1992) · British Journal of Clinical Psychology · doi:10.1111/j.2044-8260.1992.tb00997.x · Cited by 3,238
Psychometric properties of the credibility/expectancy questionnaire
Devilly, G. J., & Borkovec, T. D. (2000) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/s0005-7916(00)00012-4 · Cited by 2,295
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Tellegen, A., & Atkinson, G. (1974) · Journal of Abnormal Psychology · doi:10.1037/h0036681 · Cited by 2,196
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Cited by
Sorted by citations
Blinding and expectancy confounds in psychedelic randomized controlled trials
Muthukumaraswamy, S. D., Forsyth, A., & Lumley, T. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933434 · Cited by 324
Aday, J. S., Heifets, B. D., Pratscher, S. D., Bradley, E., Rosen, R., & Woolley, J. D. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06123-7 · Cited by 237
de la Fuente Revenga, M., Zhu, B., Guevara, C. A., Naler, L. B., Saunders, J. M., Zhou, Z., Toneatti, R., Sierra, S., Wolstenholme, J. T., Beardsley, P. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109836 · Cited by 224
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study
Cavanna, F., Muller, S. L., de la Fuente, L. A., Zamberlán, F., Palmucci, M., Janeckova, L., Kuchař, M., Pallavicini, C., & Tagliazucchi, E. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02039-0 · Cited by 157
Therapeutic effect of psilocybin in addiction: A systematic review
van der Meer, P. B., Fuentes, J. J., Kaptein, A. A., Schoones, J. W., de Waal, M. M., Goudriaan, A. E., Kramers, K., Schellekens, A., Somers, M., Bossong, M. G., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1134454 · Cited by 127
Polito, V., & Liknaitzky, P. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104706 · Cited by 130
Expectancy in placebo-controlled trials of psychedelics: if so, so what?
Butler, M., Jelen, L., & Rucker, J. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06221-6 · Cited by 100
“This phenomenon has not been explored in detail in modern clinical trials of psychedelics; however, a recent trial of microdosing of psychedelics showed that positive expectation of improvement predicted scores of well-being (Kaertner et al. 2021).”
BackgroundDoes Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
Kočárová, R., Horáček, J., & Carhart-Harris, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.661233 · Cited by 96
Self-citationSchumann, F., Steinborn, M. B., Kürten, J., Cao, L., Händel, B., & Huestegge, L. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.867978 · Cited by 90
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample
Nygart, V. A., Pommerencke, L. M., Haijen, E. C. H. M., Kettner, H., Kaelen, M., Mortensen, E. L., Nutt, D. J., Carhart-Harris, R. L., & Erritzøe, D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221101061 · Cited by 79
Expectancy Effects in Psychedelic Trials
Szigeti, B., & Heifets, B. D. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.02.004 · Cited by 81
Marschall, J., Fejer, G., Lempe, P., Prochazkova, L., Kuchar, M., Hajkova, K., & van Elk, M. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211050556 · Cited by 72
Therapeutic mechanisms of psychedelics and entactogens
Heifets, B. D., & Olson, D. E. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01666-5 · Cited by 70
Murphy, R. J., Sumner, R. L., Evans, W., Ponton, R., Ram, S., Godfrey, K., Forsyth, A., Cavadino, A., Naga, V. K., Smith, T., et al. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.03.013 · Cited by 71
Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry
Aday, J. S., Barnett, B. S., Grossman, D., Murnane, K. S., Nichols, C. D., & Hendricks, P. S. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0013 · Cited by 65
Breeksema, J. J., Niemeijer, A., Krediet, E., Karsten, T., Kamphuis, J., Vermetten, E., van den Brink, W., & Schoevers, R. (2024) · Scientific Reports · doi:10.1038/s41598-024-53188-9 · Cited by 58
Rootman, J. M., Kiraga, M. K., Kryskow, P., Harvey, K., Stamets, P. E., Santos-Brault, E., Kuypers, K. P. C., & Walsh, Z. (2022) · Scientific Reports · doi:10.1038/s41598-022-14512-3 · Cited by 57
Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review
Hovmand, O. R., Poulsen, E. D., Arnfred, S., & Storebø, O. J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231180276 · Cited by 63
Kiilerich, K. F., Lorenz, J., Scharff, M. B., Speth, N., Brandt, T. G., Czurylo, J., Xiong, M., Jessen, N. S., Casado-Sainz, A., Shalgunov, V., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02280-z · Cited by 48
Borkel, L. F., Rojas‐Hernández, J., Henríquez‐Hernández, L. A., Santana, Á., & Hernández, D. J. Q. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2295997 · Cited by 50
The need for establishing best practices and gold standards in psychedelic medicine
Feduccia, A. A., Agin-Liebes, G., Price, C. M., Grinsell, N., Paradise, S., & Rabin, D. M. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.03.083 · Cited by 44
Hartogsohn, I. (2022) · Transcultural Psychiatry · doi:10.1177/13634615221100385 · Cited by 52
Rouaud, A., Calder, A. E., & Hasler, G. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811231225609 · Cited by 44
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
Tagen, M., Mantuani, D., van Heerden, L., Holstein, A., Klumpers, L. E., & Knowles, R. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231190865 · Cited by 46
Greater subjective effects of a low dose of LSD in participants with depressed mood
Molla, H. M., Lee, R., Tare, I., & de Wit, H. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01772-4 · Cited by 44
Recent trends in the management of depression in persons with cancer
Panjwani, A. A., & Li, M. (2021) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000727 · Cited by 41
Szigeti, B., Nutt, D., Carhart-Harris, R. L., & Erritzøe, D. (2023) · Scientific Reports · doi:10.1038/s41598-023-34938-7 · Cited by 38
Psilocybin history, action and reaction: A narrative clinical review
Sharma, P., Nguyen, Q. A., Matthews, S. J., Carpenter, E., Matthews, D. B., Patten, C. A., & Hammond, C. J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231190858 · Cited by 44
Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential
Allen, J., Dames, S., Foldi, C. J., & Shultz, S. R. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02360-0 · Cited by 40
The Potential Role of Psychedelic Drugs in Mental Health Care of the Future
Gründer, G., & Jungaberle, H. (2021) · Pharmacopsychiatry · doi:10.1055/a-1486-7386 · Cited by 39
Pepe, M., Hesami, M., de la Cerda, K. A., Perreault, M. L., Hsiang, T., & Jones, A. M. P. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108247 · Cited by 36
Microdosing Psychedelics: Current Evidence From Controlled Studies
Murphy, R. J., Muthukumaraswamy, S. D., & de Wit, H. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.01.002 · Cited by 38
McIntyre, R. S., Kwan, A. T. H., Mansur, R. B., Oliveira-Maia, A. J., Teopiz, K. M., Maletic, V., Suppes, T. M., Stahl, S. M., & Rosenblat, J. D. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230902 · Cited by 33
Erritzøe, D., Barba, T., Spriggs, M. J., Rosas, F. E., Nutt, D., & Carhart-Harris, R. L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241237870 · Cited by 36
Psychedelics alter metaphysical beliefsPreprint
Timmermann, C., Kettner, H., Letheby, C., Roseman, L., Rosas, F. E., & Carhart-Harris, R. L. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/f6sjk · Cited by 34
Molecular targets of psychedelic‐induced plasticity
Jaster, A. M., Revenga, M. D. L. F., & González‐Maeso, J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15536 · Cited by 33
Feeling tired versus feeling relaxed: Two faces of low physiological arousal
Steghaus, S., & Poth, C. H. (2024) · PLoS ONE · doi:10.1371/journal.pone.0310034 · Cited by 26
Bonnelle, V., Smith, W., Mason, N. L., Cavarra, M., Kryskow, P., Kuypers, K. P. C., Ramaekers, J. G., & Feilding, A. (2022) · British Journal of Pain · doi:10.1177/20494637221114962 · Cited by 26
Psychological effects of psychedelics in adolescents
Izmi, N., Carhart-Harris, R. L., & Kettner, H. (2024) · Frontiers in Child and Adolescent Psychiatry · doi:10.3389/frcha.2024.1364617 · Cited by 26
Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome
Buzzelli, V., Carbone, E., Manduca, A., Schiavi, S., Feo, A., Perederiy, J. V., Ambert, K. H., Hausman, M., & Trezza, V. (2023) · Psychopharmacology · doi:10.1007/s00213-022-06286-3 · Cited by 22
Murphy, R. J., Sumner, R. L., Evans, W., Menkes, D. B., Lambrecht, I., Ponton, R., Sundram, F., Hoeh, N. R., Ram, S., Reynolds, L., et al. (2021) · Trials · doi:10.1186/s13063-021-05243-3 · Cited by 25
Set and setting in microdosing: an oft-overlooked principle
Hartogsohn, I., & Petranker, R. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06249-8 · Cited by 26
Hübner, S., Haijen, E. C. H. M., Kaelen, M., Carhart-Harris, R. L., & Kettner, H. (2021) · Journal of Medical Internet Research · doi:10.2196/25973 · Cited by 20
Donegan, C. J., Daldegan‐Bueno, D., Sumner, R. L., Menkes, D. B., Evans, W., Hoeh, N. R., Sundram, F., Reynolds, L., Ponton, R., Cavadino, A., et al. (2023) · Pilot and Feasibility Studies · doi:10.1186/s40814-023-01399-8 · Cited by 21
Inter-individual variability in neural response to low doses of LSD
Hutten, N. R. P. W., Quaedflieg, C. W. E. M., Mason, N. L., Theunissen, E. L., Liechti, M. E., Duthaler, U., Kuypers, K. P. C., Bonnelle, V., Feilding, A., & Ramaekers, J. G. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03013-8 · Cited by 22
Will psilocybin lose its magic in the clinical setting?
Hayes, C., Wahba, M., & Watson, S. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253221090822 · Cited by 20
Natural language signatures of psilocybin microdosing
Sanz, C., Cavanna, F., Muller, S. L., de la Fuente, L., Zamberlán, F., Palmucci, M., Janeckova, L., Kuchař, M., Carrillo, F., García, A. M., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06170-0 · Cited by 19
Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives
Kaypak, A. C., & Raz, A. (2022) · Transcultural Psychiatry · doi:10.1177/13634615221119386 · Cited by 22
Forstmann, M., Kettner, H., Sagioglou, C., Irvine, A., Gandy, S., Carhart-Harris, R. L., & Luke, D. P. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221146356 · Cited by 21
Murphy, R. J., Godfrey, K. E. M., Shaw, A. D., Muthukumaraswamy, S. D., & Sumner, R. L. (2024) · BMC Neuroscience · doi:10.1186/s12868-024-00844-5 · Cited by 19
Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research
Polito, V., & Liknaitzky, P. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241254831 · Cited by 26
How Psychedelic-Assisted Treatment Works in the Bayesian Brain
Villiger, D. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.812180 · Cited by 21
Set and Setting for Psychedelic Harm Reduction
Hartogsohn, I. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_509 · Cited by 22
Blinding and expectancy confounds in psychedelic randomised controlled trials
Muthukumaraswamy, S., Forsyth, A., & Lumley, T. (2021) · doi:10.31234/osf.io/q2hzm · Cited by 15
Keeping the promise: a critique of the current state of microdosing research
Petranker, R., Anderson, T., Fewster, E. C., Aberman, Y., Hazan, M., Gaffrey, M. S., & Seli, P. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1217102 · Cited by 19
Psychedelics and schizophrenia: a double-edged sword
Sapienza, J., Martini, F., Comai, S., Cavallaro, R., Spangaro, M., Gregorio, D. D., & Bosia, M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02743-x · Cited by 20
Kinderlehrer, D. A. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s500337 · Cited by 15
van den Berg, M., Magaraggia, I., Schreiber, R., Hillhouse, T. M., & Porter, J. H. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06106-8 · Cited by 13
Daldegan‐Bueno, D., Donegan, C. J., Forsyth, A., Sumner, R. L., Murphy, R. J., Menkes, D. B., Evans, W., Hoeh, N. R., Sundram, F., Reynolds, L., et al. (2024) · Trials · doi:10.1186/s13063-024-08384-3 · Cited by 14
Unblinding and demand characteristics in the treatment of depression
Goodwin, G. M., Croal, M., Marwood, L., & Malievskaia, E. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.02.030 · Cited by 14
Psychedelic Therapy: A Primer for Primary Care Clinicians—Ketamine
Evans, V. D., Arenas, A., Shinozuka, K., Tabaac, B. J., Beutler, B. D., Cherian, K. N., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001721 · Cited by 19
Li, H., Zhang, X., Bi, S., Cao, Y., & Zhang, G. (2021) · Healthcare · doi:10.3390/healthcare9070918 · Cited by 13
Human behavioral pharmacology of psychedelics
Strickland, J. C., & Johnson, M. W. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2021.10.003 · Cited by 16
Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study
Hartong, V., & van Emmerik, A. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2080616 · Cited by 11
“In addition, Kaertner et al. (2021) found that positive expectancy scores regarding the effects of microdosing at baseline predicted subsequent improvements in wellbeing.”
BackgroundSabat, S., Patra, S., Swain, S. N., Bej, S., Bishoyi, A. K., Sabat, G., & Padhy, R. N. (2025) · RSC Advances · doi:10.1039/d5ra07545a · Cited by 13
Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health
Ryan, R. S., Copello, A. G., & Fox, A. P. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04628-9 · Cited by 12
Haijen, E. C. H. M., Hurks, P. P. M., & Kuypers, K. P. C. (2024) · European Psychiatry · doi:10.1192/j.eurpsy.2024.8 · Cited by 12
Murphy, R. J., Sumner, R. L., Godfrey, K., Mabidikama, A., Roberts, R. P., Sundram, F., & Muthukumaraswamy, S. D. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06680-z · Cited by 14
Expectancy Effects Cannot Be Neglected in MDMA-Assisted Therapy Research
Flameling, L. J., Aday, J. S., & van Elk, M. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00692 · Cited by 12
de la Fuente Revenga, M., Zhu, B., Guevara, C. A., Naler, L. B., Saunders, J. M., Zhou, Z., Toneatti, R., Sierra, S., Wolstenholme, J. T., Beardsley, P. M., et al. (2021) · doi:10.1101/2021.02.24.432725 · Cited by 11
Bălăeţ, M., Trender, W. R., Hellyer, P. J., & Hampshire, A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1184681 · Cited by 13
Wells, A., Muthukumaraswamy, A. P. S., Morunga, E., Evans, W., Cavadino, A., Bansal, M., Lawrence, N. J., Ashley, A., Hoeh, N. R., Sundram, F., et al. (2024) · Pilot and Feasibility Studies · doi:10.1186/s40814-024-01449-9 · Cited by 10
Modzelewski, S., Stankiewicz, A., Waszkiewicz, N., & Łukasiewicz, K. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110402 · Cited by 9
The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice
Stein, C. A., Penn, A., Hope, S., Dorsen, C. G., & Mangini, M. (2022) · Journal of Midwifery & Women s Health · doi:10.1111/jmwh.13371 · Cited by 9
How Level is the 'Cognitive Playing Field'?
Martin, J. M., & Sterzer, P. (2022) · Philosophy and the Mind Sciences · doi:10.33735/phimisci.2022.9326 · Cited by 7
Zhou, L., Huimin, L., & Hua, S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318872 · Cited by 7
Psychedelic Microdosing among Young Adults from Southern California
Harlow, A. F., Hendricks, P. S., Leventhal, A. M., & Barrington‐Trimis, J. L. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2313684 · Cited by 9
Cavanna, F., Muller, S. L., de la Fuente, L. A., Zamberlán, F., Palmucci, M., Janeckova, L., Kuchař, M., Pallavicini, C., & Tagliazucchi, E. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.30.470657 · Cited by 7
Haijen, E. C. H. M., Hurks, P. P. M., & Kuypers, K. P. C. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1233585 · Cited by 7
Between enhancement and risk: A critical review of psychedelic microdosing
Totomanova, I., Haijen, E. C. H. M., Hurks, P. P. M., Ramaekers, J. G., & Kuypers, K. P. C. (2025) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2025.102129 · Cited by 6
Elsadek, M., Xie, J., & Jie, G. (2023) · HortScience · doi:10.21273/hortsci17326-23 · Cited by 8
Syed, O. A., Petranker, R., & Tsang, B. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106204 · Cited by 6
Unlocking the self: Can microdosing psychedelics make one feel more authentic?
Pop, I. A., & Dinkelacker, J. (2023) · Nordic Studies on Alcohol and Drugs · doi:10.1177/14550725231175353 · Cited by 6
Enriquez‐Geppert, S., Krc, J., O'Higgins, F., & Lietz, M. P. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2023.0095 · Cited by 5
Can the gut-brain axis provide insight into psilocybin's therapeutic value in reducing stress?
Kit, A., Conway, K., Makarowski, S., O'Regan, G., Allen, J., Shultz, S. R., Bodnar, T. S., & Christie, B. R. (2025) · Neurobiology of Stress · doi:10.1016/j.ynstr.2025.100732 · Cited by 5
Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury
Plummer, Z., Allen, J., Brand, J., Mayo, L. M., Shultz, S. R., & Christie, B. R. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111448 · Cited by 6
Jacobs, L., Banbury, S. A., & Lusher, J. M. (2022) · Sexual & Relationship Therapy · doi:10.1080/14681994.2022.2044466 · Cited by 5
Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and Potential Harms
Tariq, R. (2022) · Current Clinical Pharmacology · doi:10.2174/2772432817666220321142707 · Cited by 5
Managing expectations with psychedelic microdosing
Syed, O. A., & Tsang, B. (2023) · npj Mental Health Research · doi:10.1038/s44184-023-00044-9 · Cited by 5
Vilca-Melendez, S., Uthaug, M. V., & Griffin, J. L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.742856 · Cited by 5
Kiilerich, K. F., Lorenz, J., Scharff, M. B., Speth, N., Brandt, T. G., Czurylo, J., Xiong, M., Jessen, N. S., Casado-Sainz, A., Shalgunov, V., et al. (2023) · doi:10.31219/osf.io/gy6m9 · Cited by 5
Donegan, C. J., Daldegan‐Bueno, D., Noorani, T. N., Sumner, R. L., Forsyth, A., Evans, W., Smith, T., Hoeh, N. R., Sundram, F., Menkes, D. B., et al. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110670 · Cited by 4
Salvinorin A and Salvia divinorum: Toxicology, Pharmacological Profile, and Therapeutic Potential
Calado, S., Pires, B., Rosendo, L. M., Rosado, T., Gallardo, E., & Duarte, A. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125588 · Cited by 4
Oblak, A., Hudnik, L. K., Levačić, A., Elersič, K., Pregelj, P., & Bon, J. (2024) · Philosophical Psychology · doi:10.1080/09515089.2024.2393690 · Cited by 5
Microdosing psychedelics – Does it have an impact on emodiversity?
Pop, I. A., & Dinkelacker, J. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00208 · Cited by 4
LSD microdosing attenuates the impact of temporal priors in time perceptionPreprint
Sadibolova, R., Murray-Lawson, C., Family, N., Williams, L. T. J., Luke, D. P., & Terhune, D. B. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.14.536983 · Cited by 4
Understanding the Experience of Ketamine-Assisted Therapy and the Importance of Context
Stockwell, G., Hoeh, N. R., Fogarty, F. A., Clayden, C., & Reynolds, L. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2527299 · Cited by 3
How do psychedelics impact people with a history of non-affective psychosis? A qualitative study
Dourron, H. M., Copes, H., Grossman, D. H., Bradley, M., Nicholas, C. R. N., Turner, J. A., Allen-Clark, G., Gossage, M., & Hendricks, P. S. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1716545 · Cited by 3
Microdosing psychedelics has no impact on cognitive function in naturalistic settings
Dinkelacker, J., & Pop, I. (2023) · Journal of Psychology & Clinical Psychiatry · doi:10.15406/jpcpy.2023.14.00738 · Cited by 3
Bobak, L., Dorney, I., Kovacevich, A., & Barnett, B. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2478097 · Cited by 1
Metadata
- Authors
- Kaertner, L. S., Steinborn, M. B., Kettner, H., Spriggs, M. J., Roseman, L., Buchborn, T., Balaet, M., Timmermann, C., Erritzoe, D., & Carhart-Harris, R. L.
- Affiliations
- University of Würzburg (DE)
- Imperial College London (GB)
- ORCID
- Venue
- Scientific Reports
- Published
- 2021-01-21
- Volume
- 11
- Issue
- 1
- Pages
- 1941-1941
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC7820236
- OpenAlex
- W3122801192
- Cited by
- 145
- References
- 76
- Citations by year
- 2026: 6 · 2025: 26 · 2024: 34 · 2023: 37 · 2022: 24 · 2021: 18
- FWCI
- 19.24
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Online Publication Service of Würzburg University (Würzburg University) (submittedVersion, cc-by)
- Spiral (Imperial College London) (submittedVersion, cc-by)
- Funders
- National Institute for Health and Care Research (ACF-2013-21-501, CL-2017-21-004)
- Academy of Medical Sciences (SGL019\1063)
- Imperial College London
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Social Sciences › Psychology › Social Psychology › Psychological Well-being and Life Satisfaction
- Keywords
- psychedelic microdosing, positive expectations, placebo response, psychological well-being, state anxiety, depressive symptoms, emotional stability, psychological resilience, social connectedness, agreeableness, nature relatedness, psychological flexibility, classic psychedelics
- MeSH terms
- Adult, Affect, Anxiety, Dose-Response Relationship, Drug, Emotions, Female, Hallucinogens, Humans, Lysergic Acid Diethylamide, Male, Mental Health, Middle Aged, Motivation, Psilocybin, Quality of Life, Placebo Effect, Outcome Assessment, Health Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review